Antibody drug maker Igenica, with Dave Goeddel at the helm, raises $33 million

In its third round of venture funding, Igenica Inc. raised $33 million.

The Burlingame business, run by former Genentech Inc. scientist David Goeddel, seeks to develop antibody-based cancer medicines. It has raised $55 million total since it started in early 2009.

Third Rock Ventures, a new investor, led this round, while the Column Group, Orbimed Advisors and 5AM Ventures also gave money. Carl Gordon of Orbimed and John Diekman of 5AM Ventures work on Igenica's board of directors.